Tue, Apr 2, 2013
Four Seasons Hotel
200 Boylston Street
Boston, MA 02116
(617) 338-4400
Cost: $1700 per person
Dress Code: Business Attire
The Boston Biotech Business Development Conference is a networking forum for industry professionals offering exclusive access to the key decision makers who influence deal making and investment in the life sciences. Attendees will gain insights from presentations and panels featuring business development decision-makers from several of the world\'s leading pharmaceutical and biotechnology companies, on the current and future outlook for licensing, M&A and other business development activities in the life sciences sector. In between learning what it takes to get a deal done in biotech, the Business Development Conference offers opportunities throughout the day to network one-on-one with the industry\'s top deal makers - senior executives from biotech and pharma, leaders from Wall Street and venture capitalists.
Past participants include:
• Ad Rawcliffe, S.V.P., Worldwide Business Development, GlaxoSmithKline
• Barbara Yanni, V.P. and Chief Licensing Officer, Merck
• Robert Bagdorf, Pfizer, VP, Business Development
• Merv Turner, SVP Worldwide Licensing and External Research
• John Maraganore, CEO, Alnylam
• David Pyott, CEO, Allergan
• Adelene Perkins, CEO Infinity Pharmaceuticals
• Bob Coughlin, President, Mass Biotech Council
• Chris Gabrieli, Co-founder and Chairman, Massachusetts 2020 Foundation
• Wyc Grousbeck, CEO and Owner, Boston Celtics
• JF Formela, Partner, Atlas Ventures
| Time | Agenda |
|---|---|
| 7:00-7:30 am | Registration & Networking Breakfast |
| 7:30-7:45 am | Welcome and Opening Remarks: Rich Aldrich, Michelle Dipp, Ashley Dombkowski, David Donabedian, Steve Engen, Robert Forrester, Jean George, Steven Holtzman, Neil Kirby, John Maraganore, Brian McVeigh, Mark Miller, Adelene Perkins, Laurence Reid, Jason Rhodes, James Sabry, Rick Shea, Christoph Westphal, Barbara Yanni |
| 7:45-7:55 am | Keynote Speaker |
| 7:55-8:00 am | Deleterious Me: Whole Genome Sequencing, 23andMe, and the Crowd-Sourced Health Care Revolution |
| 8:00-8:30 am | Mergers & Acquisitions |
| 8:30-9:00 am | Large Biotech |
| 9:00-9:30 am | Payors and Providers |
| 9:30-10:00 am | Small Biotech |
| 10:00-10:30 am | Networking Break |
| 10:30-11:00 am | The West Coast Perspective |
| 11:00-11:30 am | Mid-size Biotech |
| 11:30-12:00 pm | R&D |
| 12:00-12:30 pm | Rare Diseases |
| 12:30-1:00 pm | Networking Lunch |
| 1:00-1:30 pm | Buyside |
| 1:30-2:00 pm | Accessing Biotech and Academia |
| 2:00-2:30 pm | European and Asian Perspectives |
| 2:30-3:00 pm | Networking Break |
| 3:00-3:30 pm | Venture Capital |
| 3:30-4:00 pm | New Directions in Pharma BD |
| 4:00-4:30 pm | Patient Perspectives |
| 4:30-5:00 pm | Changing Reimbursement Landscape |
| 5:00-5:30 pm | Structuring Deals: The Future |
| 5:30-6:00 pm | Lifetime Achievement Award & Cocktails and hors d'oeuvres |
| Time | Agenda |
|---|---|
| 7:15-8:00 am | Registration & Networking Breakfast |
| 8:00-8:30 am | NY Biotech Initiative |
| 8:30-8:45 am | Partnership Between FDA & Drug Development |
| 8:45-9:15 am | Biotechnology Industry Organization (BIO) Initiatives |
| 9:15-10:00 am | Networking |
| 10:00-2:00 pm | Two Concurrent Workshops (see full agendas below) Orphan Drug Summit (Oriental Ballroom) Fertility Summit (Bangkok Room) |
| 2:00-3:00 pm | Wine and cheese |
| Time | Agenda |
|---|---|
| 10:00-10:45 am | Orphan Drug Development and Regulation: Abbie Celniker, Eleven Biotherapeutics; Nick Leschly, Bluebird Bio; Arthur Tzianabos, Shire; Tim Cote, NORD |
| 10:45-11:30 am | Orphan Drug Company Strategies: JC Gutierrez-Ramos, Pfizer; Claudia Hirawat, PTC Therapeutics |
| 11:30-12:20 pm | Networking Lunch |
| 12:20-1:05 pm | Business Development and Role of VC in Orphan Drug Development: Ashley Dombkowski, 23andMe; Alan Walts, Genzyme Ventures; Christoph Westphal, Verastem |
| 1:05-1:15 pm | Patient Associations: Tim Cote, NORD |
| 1:15-2:00 pm | Commercial Strategies: Chris Adams, Formerly FoldRx/Pfizer; Tony Rosenberg, Novartis; Barry Frankel, Frankel Group |
| 2:00-3:00 pm | Wine and Cheese |
| Time | Agenda |
|---|---|
| 10:00-10:45 am | 10:00 - 10:25 am Bioenergetics in IVF: David Sable, Special Situations Life Sciences Fund |
| 10:45-11:30 am | New Advances in Fertility Treatment: Benjamin Leader, ReproSource, Inc.; Alan Penzias, Harvard Medical School, BIDMC, Boston IVF; Mitchell Rosen, University of California, San Francisco |
| 11:30-12:30 pm | Networking Lunch |
| 12:30-1:15 pm | Fertility and Aging: Jonathan Tilly, MGH & Harvard Medical School; David Sinclair, Harvard Medical School |
| 1:15-2:00 pm | Patient Advocacy: Barbara Collura, RESOLVE: The National Infertility Association; Erin Lasker, RESOLVE New England |
| 2:00-3:00 pm | Wine and Cheese |
| Name | Address | Phone |
|---|---|---|
| Four Seasons Hotel Boston | 200 Boylston Street, Boston, MA 02116 | (617) 351-2036 |
| Name | Company |
|---|---|
| Rich Aldrich | |
| Michelle Dipp | |
| Ashley Dombkowski | |
| David Donabedian | |
| Steve Engen | |
| Robert Forrester | |
| Jean George | |
| Steven Holtzman | |
| Neil Kirby | |
| Jeffrey Leiden | |
| John Maraganore | |
| Brian McVeigh | |
| Mark Miller | |
| Adelene Perkins | |
| Laurence Reid | |
| Jason Rhodes | |
| James Sabry | |
| Rick Shea | |
| Christoph Westphal |